Teriparatide Patent Expiration
Teriparatide is used for reducing the risk of bone fractures in post-menopausal women with osteoporosis. It was first introduced by Eli Lilly And Co
Teriparatide Patents
Given below is the list of patents protecting Teriparatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Forteo | US7517334 | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose |
Mar 25, 2025
(Expired) | Lilly |
| Forteo | US6977077 | Method of increasing bone toughness and stiffness and reducing fractures |
Aug 19, 2019
(Expired) | Lilly |
| Forteo | US7163684 | Method of increasing bone toughness and stiffness and reducing fractures |
Aug 19, 2019
(Expired) | Lilly |
| Forteo | US7351414 | Method of reducing the risk of bone fracture |
Aug 19, 2019
(Expired) | Lilly |
| Forteo | US6770623 | Stabilized teriparatide solutions |
Dec 08, 2018
(Expired) | Lilly |
| Forteo | US7144861 | Stabilized teriparatide solutions |
Dec 08, 2018
(Expired) | Lilly |
| Forteo | US7550434 | Stabilized teriparatide solutions |
Dec 08, 2018
(Expired) | Lilly |
Teriparatide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Teriparatide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |